The main market opportunities in Her3-targeted immunotherapies include developing ADCs, radioligand therapeutics, and bispecific antibodies. These modalities target HER3's overexpression in various ...

Chemists and chemical biologists just keep dreaming up new ways to interfere with biomolecules. That research frequently leads to promising potential medicines, and there are more and more flavors of ...

The discovery of a novel target can result in exceptionally successful classes of anticancer drugs. For example, the combined global sales in 2024 of PD1–PDL1 inhibitors — for which the first-in-class ...

Drug discovery is entering a new phase of complexity. From peptides and oligonucleotides to targeted protein degraders and other emerging modalities, many of today’s therapies require advanced ...

Folate receptor alpha (FRα) is a promising target for therapies against certain cancers, especially ovarian cancer and lung adenocarcinoma. Market opportunities are driven by innovative ADCs, small ...